Aprogen Biologics Decides to Issue 50.8 Billion Won Convertible Bonds Massive Potential Dilution of 93% Raises Capital Erosion Concerns
Aprogen Biologics has decided to issue 50.8 billion won in unregistered private convertible bonds to its affiliate Aptochrom.
The preliminary conversion price of 3,778 won is 66.8% higher than the current stock price of 2,265 won, but the potential issuance of 13,446,267 new shares represents 93.30% of the current outstanding shares, indicating massive potential dilution.
All proceeds will be used to repay existing borrowings from Aptochrom, which is a defensive capital allocation rather than growth-oriented investment, negatively impacting shareholder value.
The counterparty Aptochrom is a subsidiary where Aprogen holds a 52.28% stake, raising concerns about transaction transparency. Additionally, one outside director and the auditor were absent from the board resolution, highlighting governance risks.
Including this issuance, total outstanding convertible bonds amount to 178.8 billion won, with potential conversion into 37,873,359 shares or 262.78% of current outstanding shares, creating sustained downward pressure on the stock price.
[AI Summary]Aprogen Biologics' issuance of 50.8 billion won in convertible bonds poses severe capital erosion with a potential dilution rate of 93%, significantly harming shareholder value. The funds are used for debt repayment rather than growth, and the presence of put options and reset clauses may lead to further dilution. Combined with weak governance due to related-party transaction and board absence, investors should exercise caution.
KOSPI Filing Information
[Correction of Description] Report on Major Matters (Decision on Issuance of Convertible Bonds)